Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-02-01
2005-02-01
Priebe, Scott D. (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S455000, C435S456000, C424S093200
Reexamination Certificate
active
06849611
ABSTRACT:
This invention provides for a method of inducing a current in the heart in a subject which comprises contacting a cell of the heart of a subject with a compound in a sufficient amount to induce a current in the cell of the heart of a subject. This invention also provides a method of treating a cardiac condition in a subject which comprises contacting a cell of the heart of the subject with a compound in an amount sufficient to increase the current expression of the cell, thereby treating the cardiac condition in the subject.
REFERENCES:
patent: 6214620 (2001-04-01), John et al.
patent: 6231518 (2001-05-01), Grabek et al.
patent: 20020155101 (2002-10-01), Donahue et al.
patent: 20020187949 (2002-12-01), Rosen et al.
patent: 20020188212 (2002-12-01), Rosen et al.
patent: 0063434 (2000-10-01), None
patent: WO 0063434 (2000-10-01), None
Griscelli et al., Human Gene Therapy, 1998 9:abstract, PubMed [online] Bethesda, MD USA: United States National Library of Medicine [retrieved on Mar. 25, 2004]. Retrieved from: PubMed.*
Rosenberg et al. Science, vol. 287, 2000, p. 1751.*
Moss, PACE, vol. 20, pp. 2058-2060, 1997.*
Verma, Nature, vol. 389, pp. 239-242, 1997.*
Anderson et al., Nature, vol. 392, pp. 25-30, Apr. 1998.*
Proenza et al. The Journal of Biological Chemistry, vol. 277, 5101-5109, 2002.*
Priori et al. Nature Medicine, vol. 6, pp. 1316-1318, 2000.*
Matsuo et al. (Disapperance of complete atrioventricular block after chemotherapy for malignant lymphomas, J. Cardiol, 1999, vol. 34, abstract) Medicine [online] Bethesda, MD USA: United States National Library of Medicine [retrieved on Jan. 23, 2003].*
Nattel, et al., “Arrhythmogenic ionic remodeling-Adaptive responses with maladaptive consequences,”Trends in Cardiovascular Medicine,(2001), 11(7): 295-301; and (Exhibit 6).
Rubanyi, Gabor, “The future of human gene therapy,”Molecular Aspects of Medicine,(2001), 22:113-142. (Exhibit 7).
DiFrancesco D: The cardiac hyperpolarizing-activated current, If: Origins and developments.Prog. BiophysMol. Biol.vol. 46, No. 3, 1985, pp. 163-183; (Exhibit 2).
Zhou Z and Lipsius SL: Effect of isoprenaline on Ifcurrent in latent pacemaker cells isolated from cat right atrium: ruptured vs. perforated patch whole-cell recording methods.Pflugers Arch.vol. 423, No. 5 Pt. 6, Jun. 1993, pp. 442-447; (Exhibit 3).
Thuringer D, et al.: A hyperpolarization-activated inward current in human myocardial cells.JmolCell. Cardiol.vol. 24, No. 5, May 1992, pp. 451-455; (Exhibit 4).
Porciatti F, et al.: Block of the pacemaker current Ifin single human atrial myocytes and the effect of beta-adrenoceptor and A1-adenosine receptor stimulation.Br Jpharmacol.vol. 122, No. 6, Feb. 1991, pp. 963-969.
Yu, H, et al.: Pacemaker current exists in ventricular myocytes.Circ. Res.vol. 72, No. 1, Jan. 1993, pp. 232-236.; (Exhibit 5).
Cerbai E, et al.: The properties of the pacemaker current Ifin Human Ventricular Myocytes are modulaed by Cardiac Disease.Jmol. Cell Cardiol.vol. 33, No. 3, Mar. 2001, pp. 441-448; (Exhibit 6).
DiFrancesco D: Generation and control of cardiac pacing: the pacemaker current.Tends Cardiovasc. Med.vol. 1, 1991, pp. 250-255.
Robinson RB, et al.: Developmental change in the voltage dependence of the pacemaker current, If, in rat ventricular cells.Pflugers Arch.vol. 433, 1991, pp. 533-535; (Exhibit 7).
Fares N, et al.: Characterization of a hyperpolarization-activated current in dedifferentiated adult rat ventricular cells in primary culture.J. Physiol.vol. 506, No. 1, Jan. 1, 1998, pp. 73-82; (Exhibit 8).
Cerbai E, et al.: Influence of postnatal-development on Ifoccurrence and properties in neonatal rat ventricular myocytes.Cardiovasc. Res.vol. 42, No. 2, May 1999, pp. 416-423; (Exhibit 9).
Cerbai E, et al.: Characterization of the hyperpolarization-activated current, If, in ventricular myocytes isolated from hypertensive rats.J. Physiol.vol. 481, No. 3, Dec. 15, 1994, pp. 585-591; (Exhibit 10).
Cerbai E, et al.: Characterization of the hyperpolarization-activated current, If, in ventricular myocytes from human failing heart.Circulation.vol. 95, No. 3, Feb. 4, 1997, pp. 568-571; (Exhibit 11).
Santoro B, et al.: Interactive cloning with the SH3 domain of the N-src identifies a new brain specific ion channel protein, with homology to Eag and cyclic nucleaotide-gated channels.Proc. Natl. Sci. USA.vol. 94, No. 26, Dec. 23, 1997, pp. 14815-14820; (Exhibit 12).
Ludwig A, et al.: A family of hyperpolarization-activated mammalian cation channels.Nature.vol. 383, No. 6685, Jun. 11, 1998, pp. 587-591; (Exhibit 13).
Santoro B, et al.: Identification of a gene encoding a hyperpolarization-activated pacemaker channel of brain.Cell.vol. 93, No. 5, May 29, 1998, pp. 717-729; (Exhibit 14).
Shi W, et al.: Distribution and Prevalence of hyperpolarization-activated cation channel (HCN) mRNA Expression in Cardiac Tissues.Circ. Res.vol. 85, No. 1, Jul. 9, 1999, pp. e1-e6; (Exhibit 15).
Ishii TM, et al.: Molecular characterization of the hyperpolarization-activated cation channel in rabbit heart sinoatrial node.J. Biol. Chem.vol. 264, No. 18, Apr. 30, 1999, pp. 12835-12839; (Exhibit 16).
Ludwig A, et al.: Two pacemaker channels from human heart with profoundly different activation kinetics.EMBO J.vol. 18, No. 9, May 4, 1999, pp. 2323-2329; (Exhibit 17).
Moosmang S, et al.: Cellular expression and functional characterization of four hyperpolarization-activated pacemaker channels in cardiac and neuronal tissues.Eur. J. Biochem.vol. 268, No. 6, Mar. 2001, pp. 1646-1652; (Exhibit 18).
Altomare C, et al.: Allosteric voltage-dependent gating of HCN channels.Biophys. J.vol. 80, 2001, pp. 241a.
Protas L, et al.: Chronic neuropeptide Y exposure increases L-type Ca current in neonatal rat cardiomyocytes.Am. J. Physiol.vol. 277, No. 3 Pt. 2, Sep. 1999, pp. H940-H946. (Exhibit 19).
Kuznetsov V, et al.: β 2-adrenergic receptor actions in neonatal and adult rat ventricular myocytes.Circ. Res.vol. 76, No. 1, Jan. 1995, pp. 40-52; (Exhibit 20).
Ellingston O, et al.: Adult rat ventricular myocytes cultured in defined medium: phenotype and electromechanical function.Am. J. Physiol.vol. 265, No. 2 Pt. 2, Aug. 1993, pp. H747-H754.
Ng P, et al.: An enhanced system for construction of adenoviral vectors by the two-plasmid rescue method.Hwn.Gene Ther.vol. 11, No. 5, Mar. 20, 2000, pp. 693-699; (Exhibit 21).
He TC, et al.: A simplified system for generating recombinant adenoviruses.Proc. Natl. Acad. Sci. USA.vol. 95, No. 5, Mar. 3, 1998, pp. 2509-2514; (Exhibit 22).
Santoro B, et al.: The HCN gene family: molecular basis of the hyperpolarization-activated pacemaker channels.Ann. NY Acad. Sci.vol. 868, Apr. 30, 1999, pp. 741-764; (Exhibit 23).
Accili EA, et al.: Properties and modulation of Ifin newborn versus adult cardiac SA node.Am. J. Physiol.vol. 272, 1991, pp. H1549-H1552.
Qu J, et al.: Sympathetic innervation alters activation of pacemaker current (If) in rat ventricles.J. Physiol.vol. 526, No. 3, Aug. 1, 2000, pp. 561-569; (Exhibit 24).
Cui J, et al.: Gating of IsK expressed in Xenopus oocytes depends on the amount of mRNA injected.Gen. Physiol.vol. 104, No. 1, Jul. 1994, pp. 87-105; (Exhibit 25).
Guillemare, E, et al.: Effects of the level of mRNA expression on biophysical properties, sensitivity to neurotoxins, and regulation of the brain delayed-rectifier K+ channels Kv1.2.Biochemistry.vol. 31, No. 49, Dec. 15, 1992, pp. 12463-12468; (Exhibit 26).
Honore E, et al.: Different types of K+ channel current are generated by different levels of a single mRNA.EMBO J.vol. 11, No. 7, Jul. 1992, pp. 2465-2471; (Exhibit 27).
Honore E, et al.: Different types of K+ channel current are generated by different levels of a single mRNA.EMBO J.vol. 11, No. 7, Jul. 1992, pp. 2465-2471; (Exhibit 27).
DiFrancesco D, et al.: Direct activation of cardiac pacemaker channels by intracellular cyclic AMP.Nature.vol. 351, No. 6322, May 9, 1991, pp. 145-147; (Exhibit 29).
Kaupp UB, et al.: Molecular diversity of pacemaker ion channels.Annu, Rev. Physiol.vol. 63, 2001, pp. 235-257; (Exhibit 30).
Chang F, et al.; Effects of protein kinase
Cohen Ira S.
Robinson Richard B.
Rosen Michael R.
Yu Han-Gang
Cooper & Dunham LLP
Priebe Scott D.
Research Foundation of State University of New York
The Trustees of Columbia University in the City of New York
White John P.
LandOfFree
Implantation of biological pacemaker that is molecularly... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Implantation of biological pacemaker that is molecularly..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Implantation of biological pacemaker that is molecularly... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3490926